TSE:4503Pharmaceuticals
Astellas Pharma (TSE:4503) Stock Can Margin Gains Outrun Patent Risks
Astellas Pharma stock came into this earnings print with a solid recent run and a modest P/E discount to its pharmaceutical peers, yet the real story is in the profit engine. The headline is margin power. Q1 fiscal 2027 basic earnings per share of ¥79.15 on revenue of ¥640,914m helped push trailing 12 month net margin to 16%, far above the 4.2% level a year earlier. Today’s price reaction reflects investor judgment on whether that profitability shift is durable or just a bright spot against...